216 related articles for article (PubMed ID: 20884247)
1. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
Friedlander TW; Weinberg VK; Small EJ; Sharib J; Harzstark AL; Lin AM; Fong L; Ryan CJ
Urol Oncol; 2012; 30(4):408-14. PubMed ID: 20884247
[TBL] [Abstract][Full Text] [Related]
2. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer.
Friedlander TW; Weinberg VK; Huang Y; Mi JT; Formaker CG; Small EJ; Harzstark AL; Lin AM; Fong L; Ryan CJ
Oncol Rep; 2012 Jan; 27(1):3-9. PubMed ID: 21971890
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Miyata Y; Sakai H; Hayashi T; Kanetake H
Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
[TBL] [Abstract][Full Text] [Related]
5. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
[TBL] [Abstract][Full Text] [Related]
8. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.
Attia S; Holen KD; Thomas JP; Richie K; Dzelak T; Teeter K; Warren D; Bilger A; Fine J; Eickhoff J; Drinkwater N; Mulkerin D; Morgan-Meadows S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):44-54. PubMed ID: 18322441
[TBL] [Abstract][Full Text] [Related]
9. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
[TBL] [Abstract][Full Text] [Related]
10. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial.
Fairey AS; Courneya KS; Field CJ; Bell GJ; Jones LW; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):721-7. PubMed ID: 12917202
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
12. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
[TBL] [Abstract][Full Text] [Related]
13. Altered regulation of insulin-like growth factor binding protein-1 in patients with polycystic ovary syndrome.
Carmina E; Stanczyk FZ; Morris RS; Lee PD; Savjani G; Lobo RA
J Soc Gynecol Investig; 1995; 2(6):743-7. PubMed ID: 9420884
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
15. Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.
Serrano D; Baglietto L; Johansson H; Mariette F; Torrisi R; Onetto M; Paganuzzi M; Decensi A
Clin Cancer Res; 2005 Mar; 11(5):2083-8. PubMed ID: 15756035
[TBL] [Abstract][Full Text] [Related]
16. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
17. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma.
Vainas G; Pasaitou V; Galaktidou G; Maris K; Christodoulou K; Constantinidis C; Kortsaris AH
J Exp Clin Cancer Res; 1997 Mar; 16(1):119-26. PubMed ID: 9148872
[TBL] [Abstract][Full Text] [Related]
18. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
[TBL] [Abstract][Full Text] [Related]
19. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
[TBL] [Abstract][Full Text] [Related]
20. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
